Exploring Maintenance Strategies Post Autologous Transplant

Opinion
Video

Panelists discuss how to optimize maintenance therapy following autologous stem cell transplantation by evaluating factors such as duration, drug selection, and risk-adapted approaches to maximize long-term outcomes in multiple myeloma patients.

Current Time 0:00
Duration 2:46
Loaded: 5.89%
Stream Type LIVE
Remaining Time 2:46
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Newsletter

    Stay up to date on practice-changing data in community practice.

    Subscribe Now!
    Recent Videos
    Diagnostic Challenges in Myelofibrosis: Distinguishing Prefibrotic Disease_
    Diagnostic Challenges in Myelofibrosis: Distinguishing Prefibrotic Disease_
    The Evolving Landscape of Myelofibrosis: Current Understanding and Clinical Patterns
    The Evolving Landscape of Myelofibrosis: Current Understanding and Clinical Patterns
    Insights from COCOON: Prophylactic Dermatologic Management With Amivantamab + Lazertinib in Advanced NSCLC
    Insights from COCOON: Prophylactic Dermatologic Management With Amivantamab + Lazertinib in Advanced NSCLC
    1L Treatment for Advanced NSCLC
    1L Treatment for Advanced NSCLC
    3 experts are featured in this series.
    Recap: ELCC 2025 Highlights
    3 experts are featured in this series.
    Presented at ELCC 2025: Key Takeaways From KRYSTAL-7
    3 experts are featured in this series.
    ELCC 2025: Insights From the MARIPOSA Study
    3 experts are featured in this series.
    LAURA Study: NGS Testing in Diagnosis of NSCLC
    3 experts are featured in this series.
    Exploring Updates From KEYNOTE-799 at ELCC 2025
    1 expert is featured in this series.
    Long-Term Outcomes of Ruxolitinib Therapy in Patients With cGVHD
    Related Content
    Promising Trials Expand Approaches Across Multiple Myeloma Settings

    Promising Trials Expand Approaches Across Multiple Myeloma Settings

    John M. Burke, MD
    April 14th 2025
    Article

    John M. Burke, MD, highlights findings from the AQUILA, DREAMM 7, and MajesTEC-5 trials in multiple myeloma.

    Read More

    Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM

    Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM

    Binod Dhakal, MD, MS;Jordyn Sava
    June 14th 2024
    Podcast

    In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

    Listen

    Follow-Up With Teclistamab Shows Durability and Optimization of Dosing

    Follow-Up With Teclistamab Shows Durability and Optimization of Dosing

    Targeted Oncology Staff
    April 11th 2025
    Article

    In a live virtual event, Attaya Suvannasankha, MD, discussed the MajesTEC-1 trial of teclistamab and approaches to mitigation of cytokine release syndrome.

    Read More

    Advancing Myeloma Treatment With Blood-Based MRD Testing

    Advancing Myeloma Treatment With Blood-Based MRD Testing

    Jordyn Sava;Ben Derman, MD
    February 15th 2024
    Podcast

    In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

    Listen

    Moore Considers the Ide-Cel Subgroup Analyses and QOL in Myeloma

    Moore Considers the Ide-Cel Subgroup Analyses and QOL in Myeloma

    Targeted Oncology Staff
    April 8th 2025
    Article

    During a live event, Patrick Moore, MD, discussed the KarMMa-3 subgroup analyses and quality of life for patients with relapsed/refractory multiple myeloma.

    Read More

    Analyzing Ide-cel’s Trade-offs of Efficacy and Toxicity in Myeloma

    Analyzing Ide-cel’s Trade-offs of Efficacy and Toxicity in Myeloma

    Targeted Oncology Staff
    March 25th 2025
    Article

    During a live event, Patrick Moore, MD, discussed the superior efficacy with ide-cel vs standard care in relapsed/refractory multiple myeloma.

    Read More